Navigation Links
Questcor Recognized by Child Neurology Foundation for Outstanding Corporate Responsibility and Leadership
Date:2/21/2012

be classified as an ultra-orphan disease. For comparison, orphan disease designation pertains to diseases that affect fewer than 200,000 people in the US. IS patients experience rapid, characteristic muscular contraction or extensions lasting one to two seconds and occurring in clusters ranging from a few spasms to more than 100 spasms per cluster. Often, in the beginning, the attacks are brief, infrequent and not typical, so it is quite common for the diagnosis to be delayed. Frequently, due to the pattern of the attacks and the cry that an infant gives during or after an attack, the attacks are sometimes initially thought to be due to colic or gastric distress. 

About the Child Neurology Foundation

Founded in October 2000, the Child Neurology Foundation was created as the outreach and philanthropic arm of the Child Neurology Society. Members of the CNS include more than 1,300 child neurologists from the United States, Canada, as well as more than 30 other countries around the world.

The Foundation's mission is to advocate for children and adolescents with neurologic and developmental disorders; fund neurologic research of young investigators; promote awareness of career opportunities in child neurology; provide public, professional, and patient education programs; and support the activities and mission of the CNS.

For more information on the CNF, please visit www.childneurologyfoundation.org.

About Questcor Pharmaceuticals

Questcor is a biopharmaceutical company whose products help patients with serious, difficult-to-treat medical conditions. Questcor's specific areas of focus are in the fields of neurology and nephrology and the company is currently supporting research efforts in a variety of conditions having significant unmet medical need.  Questcor was recently selected by Forbes as the #1 rated small company in America. For more informati
'/>"/>

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Questcor Pharmaceuticals Appoints Scott M. Whitcup, M.D., to Board of Directors
2. Questcor Pharmaceuticals Responds to Questions From Investor Blog
3. Questcor Pharmaceuticals Issues Statement
4. Questcor Pharmaceuticals Reports Strong Finish to 2011
5. Questcor Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference on November 30, 2011
6. Questcor Pharmaceuticals to Present at CLSAs 4th Annual AsiaUSA Forum on November 7, 2011
7. Questcor and Child Neurology Foundation Support the 3rd Annual Infantile Spasms (IS) Awareness Week
8. Questcor Reports Third Quarter Financial Results
9. Questcor to Report Third Quarter 2011 Earnings and Conduct Conference Call on October 25, 2011
10. Questcor Pharmaceuticals Announces Preliminary Operating Metrics for Third Quarter 2011
11. Questcor Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on September 28, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... 2015 Celtaxsys, Inc., a clinical stage pharmaceutical ... rare and orphan inflammatory disease indications, announced today that ... Drug Administration (FDA) to begin a Phase 2 clinical ... adult CF patients in the US. The regulatory submissions ... will be filed soon after. This groundbreaking clinical ...
(Date:7/6/2015)... SOUTH SAN FRANCISCO, Calif. , July 6, 2015 ... leading global pharmaceutical company, and Oculeve, a development-stage medical ... eye disease, today announced that they have entered into ... an all-cash transaction.  Under the terms of the agreement, ... payment and commercialization milestone payments related to Oculeve,s lead ...
(Date:7/6/2015)... SHENZHEN, China , July 6, 2015 China ... CNIT), a leading provider of integrated cloud-based platform, exchange, ... , today announced that the Company launched its mobile ... age of accessible healthcare services on mobile devices. The ... District Health and Family Planning Bureau and Shenzhen News ...
Breaking Medicine Technology:Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 2Allergan to Acquire Oculeve Dry Eye Disease Development Programs 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 4CNIT Launches the Mobile App for Healthcare One Pass 2CNIT Launches the Mobile App for Healthcare One Pass 3CNIT Launches the Mobile App for Healthcare One Pass 4
... 8 Cell Therapeutics, Inc. (CTI),(Nasdaq and ... data for the,Zevalin(R) ([90Y]-ibritumomab tiuxetan) First-line Indolent ... Hematology (ASH) 50th Annual Meeting by,Morschhauser, et ... (PFS) following Zevalin consolidation therapy for patients ...
... Patients with non-valvular,atrial fibrillation receiving either 30 mg ... oral Factor Xa inhibitor, experienced comparable,safety and tolerability ... II data presented today at the 50th Annual ... Francisco. These findings are the first results,from ...
Cached Medicine Technology:Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 2Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 3Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 4Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 5New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation 2New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation 3New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation 4New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation 5
(Date:7/6/2015)... ... July 06, 2015 , ... Invitation to ... yet there is a large gap between the unmet health priorities in the ... health outcomes and reduce unnecessary or ineffective treatments or procedures. , This milestone ...
(Date:7/6/2015)... ... 06, 2015 , ... The Asian-Pacific market for rheumatoid arthritis therapeutics reached a ... at a CAGR of over 3.2 percent in the years to come to hit ... mainly spurred by an anticipated launch of a number of promising pipeline candidates and ...
(Date:7/6/2015)... , ... July 06, 2015 , ... ... reimbursement for radiology services and ADVOCATE is leading the transition. ADVOCATE, the only ... expertise with their Top 10 Tips for ICD-10. The ten tips are timely ...
(Date:7/6/2015)... ... July 06, 2015 , ... Longevity, the highest ... with Woodbridge Walk-In Urgent Care to offer on-site health screenings. These ultrasound screenings ... Screenings are affordable and accurate and run about an hour long with same ...
(Date:7/6/2015)... ... July 06, 2015 , ... Seedstock today announced Pierre ... address at the 4th Annual Seedstock Sustainable Agriculture Conference – “Innovation and the Small ... , held at the University of California-San Diego, will explore solutions and methodologies that ...
Breaking Medicine News(10 mins):Health News:Columbia Nursing Nairobi Summit: Setting a Clinical Research Agenda for Africa 2Health News:APAC Rheumatoid Arthritis Therapeutics Market to Reach Value of USD 6.9 Billion by 2021, Says GBI Research in Its New Report Now Available at MarketPublishers.com 2Health News:ADVOCATE Takes the Lead to Ensure ICD-10 Success: “Top 10 Tips for ICD-10” 2Health News:Woodbridge Walk-In Offers Affordable Early Detection Health Screenings Through Longevity 2Health News:Seedstock Names Go Green Agriculture Founder and CEO as 2015 Sustainable Agriculture Conference Keynote Speaker 2Health News:Seedstock Names Go Green Agriculture Founder and CEO as 2015 Sustainable Agriculture Conference Keynote Speaker 3Health News:Seedstock Names Go Green Agriculture Founder and CEO as 2015 Sustainable Agriculture Conference Keynote Speaker 4
... Sciences is launching an action tank, with start-up funds from ... the most promising strategies against global health crises. The Gates ... phase. , The new team, called the Global Health ... executive director of the Global Fund to Fight AIDS, TB ...
... headache and watery eyes,are often attributed to the common ... to the American Academy of Allergy, Asthma &,Immunology (AAAAI)., ... a cold during the,winter months when they,re actually experiencing ... Committee. "Cold and,allergy symptoms can be very similar, making ...
... are far more likely to be infected with Hepatitis ... often do not get treatment for their liver disease ... , Against this epidemiological background, the article by ... patients, represents an important study in the field, write ...
... the hallmark of Alzheimer,s disease, are clumps of ... this devastating neurodegenerative disease. , While effective ... University of Illinois at Chicago chemists suggests a ... professor of chemistry, and his students managed to ...
... to discuss new Medicaid generic prescription drug,reimbursement rule and ... his,power to make sure the legislative fix is considered ... be fully implemented in early,2008, will grossly underpay pharmacists ... Brad Hall, Executive Director of the Kentucky Pharmacists Association, ...
... CHARLES TOWN, W.Va., Dec. 3 ReBuilder Medical,Technologies, ... the art,electronic devices for diabetic peripheral neuropathy, Molluscum,Contagiosum, ... (Logo: http://www.newscom.com/cgi-bin/prnh/20061128/REBUILDERLOGO ), "Corporate ... Daena,Carter, CFO of RBRM. "Full disclosure will be ...
Cached Medicine News:Health News:UCSF launches 'action tank' to advance promising global health strategies 2Health News:Your Stuffy Nose Could Mean More Than a Cold 2Health News:Treating patients with psychiatric disorders for hepatitis C 2Health News:UIC chemists characterize Alzheimer's neurotoxin structure 2Health News:Kentucky Pharmacists Event Urging Senate Minority Leader McConnell to Fix Flawed Medicaid Drug Reimbursement Rule 2Health News:ReBuilder Medical Technologies, Inc. Reports Doubled Profits for October 2
... white LED (Light Emitting Diode) light source, coupled ... the freedom of using a slit lamp anywhere ... about 1.5 lbs. (0.68 kg) with its battery ... Its ergonomic, portable design and convenient carrying ...
Powerful LED Illumination , The ultrabright and compact 3S LED HeadLight from HEINE for Powerful, coaxial illumination...
... Abnormal Control Serum is intended for monitoring the ... assays. It is for in vitro diagnostic use ... format, the control offers up to ten days ... control is to be used in accordance with ...
e-MDs Bill practice management system is used in the medical billing cycle....
Medicine Products: